ADMA ADMA Biologics

NASDAQ
$13.63

ADMA Biologics (ADMA) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal Bearish Selling ran elevated versus ADMA's own trailing one-year pace, with 94% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 2 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
2
5 transactions
Purchases
$0
0 shares
Sales
$2.2M
178,000 shares
Net activity
-$2.2M
purchases less sales

How much of that selling was preplanned? 94% planned / 6% discretionary

10b5-1 plan sales $2.1M 4 transactions · 168,000 shares
Discretionary sales $139.2K 1 transaction · 10,000 shares

Largest single sale: $1.3M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: May 27, 2026 , by Grossman Jerrold B .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Grossman Adam S 2 fills President and CEO Sell 10b5-1 21,000 $13.72 $288.1K 2,070,777 −1% of holding
Guiheen Lawrence P. Director Sell 10,000 $13.92 $139.2K 63,599 −13.6% of holding
Grossman Adam S 2 fills President and CEO Sell 10b5-1 147,000 $12.00 $1.8M 2,112,777 −6.5% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.